STALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Nov 5, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of providing pain relief for patients undergoing laparoscopic cholecystectomy, a surgery to remove the gallbladder. The researchers want to compare the effectiveness of a local anesthesia technique that only numbs the small cuts made during the surgery (called trocar sites) with a newer method that combines this local anesthesia with an additional technique known as the STALL block, which targets deeper areas for better pain control. They hope that the STALL method will provide better pain relief than just using local anesthesia alone.
To participate in this study, you must be at least 18 years old and scheduled for either elective (planned) or emergency gallbladder surgery. However, if you are pregnant, have certain medical conditions, or are unable to give informed consent, you may not be eligible. If you join the trial, you can expect to receive one of the two pain relief methods during your surgery, and the results will help doctors understand the best way to manage pain after gallbladder surgery in the future. The trial is currently recruiting participants, and everyone is welcome regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients scheduled for elective or emergency LCC, aged over 18 and able to give an informed consent.
- Exclusion Criteria:
- • Age under 18 years, chronic daily opioid and/or pain tolerance / pain threshold -modifying medication use (abuse), pregnancy, known allergy to local anesthetics, diagnosed severe coagulopathy and incapability to give informed consent for whatever reason.
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Espoo, Karvasmäentie 8, Finland
Espoo, Uusimaa, Finland
Patients applied
Trial Officials
Henna Sammalkorpi, MD, PhD
Study Director
Helsinki UCH
Hanna Lampela, MD, PhD
Study Director
Helsinki UCH
Jukka Harju, MD, PhD, Doc
Study Director
Helsinki UCH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported